1. Resource use and costs in high-risk symptomatic peripheral artery disease patients with diabetes and prior acute coronary syndrome: a retrospective analysis.
- Author
-
Reed Chase M, Friedman HS, Navaratnam P, Heithoff K, and Simpson RJ Jr
- Subjects
- Adrenergic beta-Antagonists therapeutic use, Aged, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Clopidogrel, Costs and Cost Analysis, Diabetic Angiopathies diagnosis, Diabetic Angiopathies drug therapy, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Longitudinal Studies, Male, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease drug therapy, Retrospective Studies, Risk Factors, Ticlopidine analogs & derivatives, Ticlopidine therapeutic use, United States, Acute Coronary Syndrome complications, Diabetic Angiopathies economics, Health Resources statistics & numerical data, Peripheral Arterial Disease economics
- Abstract
Objectives: As the prevalence of peripheral artery disease (PAD) increases there is growing concern about the associated healthcare burden. This burden has not been well-characterized in high-risk patients with concurrent diabetes and/or acute coronary syndrome (ACS). The objective of this analysis was to assess comorbidities, medication use, outcomes, services and costs for 3 high-risk symptomatic PAD groups., Methods: This retrospective longitudinal analysis used the MarketScan Commercial Claims and Encounters Database (2005-2013). The 3 high-risk symptomatic PAD groups were (1) symptomatic PAD with/without diabetes, (2) symptomatic PAD with/without prior ACS, and (3) symptomatic PAD with/without diabetes and prior ACS. The study time frame was a period of 1-year before the earliest date of a symptomatic PAD record and 3 years post., Results: In all, 16,663 symptomatic PAD patients were identified across the three risk groups. Mean age ranged from 66.4-67.4 years; the majority (55.0%-63.3%) were men. At 3 years post index, patients with symptomatic PAD and a risk factor had significantly higher use of beta-blockers, ACE inhibitors and statins (P<0.0007), and higher rates of all-cause and symptomatic PAD-related medical services, diagnoses and procedures (P<0.05). Clopidogrel and statins were used by ≤ 41.2% and ≤ 66.7% of symptomatic PAD patients without risk, respectively, and ≤ 68.9% and ≤ 80.2% of patients with risks. All cause and symptomatic PAD-related treatment costs (P<0.0001) were higher for symptomatic PAD patients with risks versus patients without risks where annualized all-cause cost differences ranged from $7,482 to $13,504 and annualized PAD-related cost differences ranged from $605 to $1,997., Conclusions: Symptomatic PAD patients with diabetes and/or prior ACS have significantly higher medical resource use and costs compared to symptomatic PAD patients without these risk factors. The utilization rate of secondary prevention therapies is suboptimal; therefore, greater effort must be made to increase utilization and optimize treatment to minimize the impact of symptomatic PAD.
- Published
- 2016
- Full Text
- View/download PDF